#### **Supplemental Figures, videos and tables**

## hsa-miRNA-548v controls the viscoelastic properties of human cardiomyocytes and improves their relaxation rates

Eva Vermersch<sup>1,2</sup> PhD, Salomé Neuvendel<sup>1</sup>, Charlene Jouve<sup>1</sup>, Andrea Ruiz Velasco<sup>1</sup>, Céline Pereira<sup>1</sup>, Magali Seguret <sup>1</sup>, Marie-Elodie Cattin-Messaoudi<sup>2</sup> PhD, Sofia Lotfi<sup>2</sup>, Thierry Dorval<sup>2</sup> PhD, Pascal Berson<sup>3</sup> PhD, and Jean-Sébastien Hulot<sup>1,4\*</sup> MD PhD.



## Figure Supplemental 1: HTS quality control and expression profile of hsa-miR-548V

**A** HTS Quality control: impact of different concentrations of miR negative control (grey) compared to the addition of transfection media only (black), or miR-506-3p (red) on amplitude, mean contraction velocity and mean relaxation velocity. N=3 screens. \*\*\*p<0.001, \*\*\*\*<p<0.0001 for miR-506-3p as compared to controls, ANOVA with post-hoc comparisons. **B** MiRNATissueAtlas2 results for hsa-miR-548v. **C** Fantom5 results for hsa-miR-548v showing an exclusive expression in endothelial cells





В





TNNT2/ACTN/DAPI

TNNT2/ACTN/DAPI

#### Figure Supplemental 2: Quality control of hiPS control cell lines:

A Control-1, Control-2 and Control-3 pluripotency evaluation by immunofluorescence (left) and qPCR (right). B Quality control of TroponinT2 positive cells by flow cytometry for Control-1 (n=17), Control-2 (n=19) and Control-3 (n=16). C Representative images of control cardiomyocytes stained for TroponinT2 (Red), Actinin (Green) and DAPI (Blue). Scale bar =  $30 \mu m$ .



**Figure Supplemental 3: hsa-miR-548v effect in hiPSC-CM-based engineered cardiac tissues (hECT)** A Experimental workflow. The green arrow represents the experiments until hECT formation. The grey arrow corresponds to baseline and 3 days post transfection hECTs' video recordings. The orange arrow corresponds to the post-processing of videos to acquire and analyze motion parameters. **B** Representative top and side view of hECT. **C** Evaluation of hsa-miR-548v expression levels 3 days after transfection (n=3 per groups). **D** Average beat rate according to pacing. (n=5 per group). **E** Representative recordings of beat-to-beat motion from hECTs transfected with hsa-miR-548v (orange) or miR negative control (grey). Averaged contraction/relaxation cycle recorded from ECTs transfected with hsa-miR-548v (orange) or miR negative control (grey). **F** Relative mean relaxation velocities in hECT 3 days after transfection with hsa-miR-548v (n=3) or miR negative control (n=3). (\*, p< 0.05). **G** Relative developed force in hECT 3 days post transfection with hsa-miR-548v (n=3).



### Figure Supplemental 4: Calcium imaging in hiPSC-CMs monolayers

**A** Area under the curve – calcium transient analysis in fluo4 loaded hiPSC-CMs transfected with miR negative control (n=42) or hsa-miR-548v (n=41).

**B** Mean relaxation velocity extracted from bright field records of hiPSC-CMs transfected with miR negative control (n=41) or hsa-miR-548v (n=41). \*, P<0.05, T test.



**Figure Supplemental 5: Analysis of RNA-sequencing between control and hsa-miR-548v transfected hiPSC-CMs. A** Principal component analysis based on the 1000 most variant genes. **B** Top 50 differentially expressed genes in hsa-miR-548v vs miR negative control. **C-K** level of expression of **C** *NNPA*, **D** *NNPB*, **E** *DES*, **F** *ANKDR1*, **G** *ANKDR2*, **H** *RYR2*, **I** *MYH6*, **J** *MYH7*, **K** *TNNI3* 



# Figure Supplemental 6: Pathway analysis of RNA-sequencing between control and hsa-miR-548v transfected hiPSC-CMs.

**A** GSEA enriched pathways.

**B** Down-regulation of the MAPK cascade in response to hsa-miR-548v transfer.



Figure Supplemental 7: Differential analysis of key genes of cardiomyocytes architecture

Supplemental Video V1: Bright field (BF) recording during HTS

Supplemental Video V2: Vector flow analysis of BF analysis during HTS

**Supplemental Video V3:** Beating ECT generated as linear macrostructure imaged by high-speed microscopy

**Supplemental Video V4-V6:** Beating ring-shaped ECT generated with the three control hiPS cell lines.

Supplemental Video V7: Beating ring-shaped ECT generated with the BRAF T599R mutated hiPSC-CMs

**Supplemental Table 1:** Overexpressed genes in hsa-miR-548v transfected cells compared to miR negative control transfected cells

**Supplemental Table 2:** Underexpressed genes in hsa-miR-548v transfected cells compared to miR negative control transfected cells

Supplemental Table 3: List of oligonucleotides used for CRISPR-Cas9 experiments

#### Figure 5E full unedited gels





#### Figure 6C full unedited gels

6D



Vinculin





pERK

ERK 1/2



Figure 6D full unedited gels

ANKRD1/CARP1



Vinculin

